Latest astrocytoma Stories
RnRMarketResearch.com adds “Malignant Glioma – Pipeline Review, H1 2015” report to its store.
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma
- Results from Phase I program in glioblastoma multiforme presented at ASCO earlier this year NORTH CHICAGO, Ill., Aug.
Brian Olson Discusses Diagnosis, Importance of Patient Resources and Support Chicago, IL (PRWEB) July 25, 2014 There are 700,000 people in the U.S.
("Leading Edge" Gamma Knife Treatment, led by Christopher Duma, M.D., FACS and his team of researchers, offers hope to patients with Glioblastoma Multiforme) NEWPORT BEACH, Calif.,
HOUSTON, June 27, 2014 /PRNewswire/ -- The Burzynski Research Institute, Inc.
Neurosurgeon Peter Nakaji has published four academic papers with colleagues, each discussing technology and the intraoperative diagnosis of brain tumors. Phoenix,
- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO,
Comprehensive genomic analysis of low-grade brain tumors sorts them into three categories, one of which has the molecular hallmarks and shortened survival of glioblastoma multiforme, the most lethal of brain tumors.
The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.